Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... NEW YORK, Jan. 12, 2011 InstaCare Corp. ... prescription and non-prescription diagnostics, home testing products for ... direct to patient diabetes programs, and a leading ... technologies, today announced that the company,s Board of ...
... 2011 At the 29th Annual J.P. Morgan Healthcare Conference, ... that based on a preliminary review of 2010 results, it ... more than $3.5 billion compared to 2009. Adjusted cash earnings ... the midpoint of the company,s latest forecast of $3.37 to ...
Cached Medicine Technology:InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2Watson Announces Preliminary Financial Performance for FY 2010 2Watson Announces Preliminary Financial Performance for FY 2010 3Watson Announces Preliminary Financial Performance for FY 2010 4
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... Kristen Fischer HealthDay ... Slimming down may help ease the hot flashes that often ... debilitating for more than 50 percent of menopausal women, said ... and reproductive science at the Icahn School of Medicine at ... menopausal women experience more than 10 hot flashes a day, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... that break out regularly between outspoken celebrities or loudmouth pundits ... relationship, a new study suggests. High amounts of Twitter ... the couple is in a long-term relationship, according to findings ... turn, that friction can lead to cheating and breakups, the ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... Patient Care Model Significantly Improves Patient OutcomesEL SEGUNDO, ... provider of kidney care services for those diagnosed ... findings of a study revealing DaVita,s IMPACT(TM) (Incident ... program can significantly reduce mortality rates for new ...
... Pediatric surgeons are able to repair complex heart defects ... but that doesn,t necessarily mean a happy ending for ... great quality of life and others, with the same ... pediatric medical centers throughout the United States shows that ...
... HOUSTON (March 29, 2009) The allergen breathed in by ... MMP7 that activates a cascade of events to prompt an ... College of Medicine ( www.bcm.edu ) in Houston in a ... Immunology . , In particular, MMP7 activates interleukin 25, a ...
... the same for bare metal or drug-eluting devices, study found, ... that stent thrombosis, a blood clot inside a stent, is ... no difference in the clot risk for either drug-eluting ... After a heart attack, many patients undergo a treatment ...
... Health Ltd. affiliate program is the answer for individuals who want to ... benefits as well as demand. ZEO Health has created a risk-free, ... today and find out more about the affiliate program. , ... New ...
... Michael Harbut, M.D., MPH, co-director of the National ... Barbara Ann Karmanos Cancer Institute in Detroit, MI, and ... Wayne State University , announced the use of ... asbestos-related lung disease. The announcement was made at the ...
Cached Medicine News:Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2Health News:No Increase in Clots With Drug-Eluting Stents 2Health News:No Increase in Clots With Drug-Eluting Stents 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3
Nitinol Flat Wire Basket...
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli...
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Medicine Products: